{
    "symbol": "RCEL",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-23 21:16:03",
    "content": " To begin with we had a strong top line commercial revenue performance with $9.4 million in Q4 2022, which is a 37% increase over the same period in the prior year. In the three months ended December 31, 2022, our commercial revenue, which excludes BARDA revenue increased by 37% to $9.4 million, compared to $6.8 million in the same period in 2021. Total revenue which includes BARDA revenue increased by 36% to $9.5 million, compared to $6.9 million in the same period in 2021. Total operating expenses for the quarter increased by 2% to $15 million, compared to $14.8 million in the same period in 2021. Soft tissue repair and vitiligo trial participants were in a less costly fall phases this period, compared to more costly recruitment and treatment phases in the prior period, along with lower expenses for sponsored research agreements toward pipeline development. For the full year ended December 31, 2022, our commercial revenue increased by 36% to $34.1 million compared to $25.1 million in the same period in 2021. The pediatric burn study was closed for enrollment, soft tissue repair and vitiligo trial participants were in less costly follow-up phases in this period compared to more costly recruitment and treatment phases in the prior period and a lower expense for sponsored research towards pipeline development in the current period. Your line is now open. Your line is now open. Your line is now open. Your line is now open. I was hoping you might talk a little bit about what your expectations are with regard to sort of the dynamics in the soft tissue market, relative to your experience with large burns in terms of kind of number of cases that RECELL might be appropriate for, let's say, per week or per month in the centers you're going to attack. Your line is now open."
}